Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
"Exciting Race" Between LLY & NVO, Tariffs Remain Long-Term Overhang
12:00pm, Monday, 06'th Oct 2025
Lee Brown sees lots of potential in the weight loss drug space, noting Eli Lilly (LLY) and Novo Nordisk (NVO) as the two companies he expects to lead. He points to "incredible" discounts and expanded
2 Beaten-Down Stocks Primed for a Comeback
02:30pm, Sunday, 05'th Oct 2025
Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present.
Novo Nordisk: The Bottom Is In
08:18am, Saturday, 04'th Oct 2025
NVO trades at a rare dislocation with a forward P/E ~15% below sector and EPS growth ~66% above, primed for the 2026 healthcare re-rating. Its semaglutide engine (Wegovy growth, CagriSema pipeline, hi
Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated
04:20pm, Friday, 03'rd Oct 2025
Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e
Novo plans online launch for obesity pill once approved, Bloomberg News reports
01:26pm, Friday, 03'rd Oct 2025
Danish drugmaker Novo Nordisk said it plans to make its new obesity pill available through telehealth platforms like Ro and WeightWatchers once it gets U.S. approval, Bloomberg News reported on Friday
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Friday, 03'rd Oct 2025
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk Is Primed For A Post-Earnings Recovery (Earnings Preview)
05:52am, Friday, 03'rd Oct 2025
Novo Nordisk's Q2 2025 results showed resilient revenue growth, but profit guidance was cut due to U.S. competition, compounded drugs, and currency headwinds. I see the upcoming Q3 earnings and Alzhei
Buy Novo Nordisk Stock as Health Names Return to Favor, Analyst Says
12:52pm, Thursday, 02'nd Oct 2025
HSBC made the call as it listed the pharma stocks it sees as best positioned to play a recovery in the sector.
Can Novo Nordisk's Restructuring Program Drive its Return to Growth?
12:16pm, Thursday, 02'nd Oct 2025
NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit – NVO
04:18pm, Wednesday, 01'st Oct 2025
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Why Shares in Novo Nordisk Bumped Higher Today
01:27pm, Wednesday, 01'st Oct 2025
Shares in Novo Nordisk (NVO 6.09%) were up 6% by 11:30 a.m. on Wednesday.
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
08:45am, Wednesday, 01'st Oct 2025
NEW YORK , Oct. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The l
Novo Nordisk is still a 'Buy' at Goldman Sachs
07:44am, Wednesday, 01'st Oct 2025
Goldman Sachs has repeated a 'Buy' rating on Ozempic and Wegovy maker Novo Nordisk (NYSE:NVO), but cautions that earnings momentum into 2026 remains uncertain. The American broker expects the Danish
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
04:41pm, Tuesday, 30'th Sep 2025
LOS ANGELES , Sept. 30, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo Nordisk
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
